We develop novel allogeneic iPSC-derived natural killer (NK) and T cell products with the potential to overcome many limitations of earlier generation cell therapies and to significantly expand the effectiveness and accessibility of cell therapies for both blood and solid cancers.

Our advanced iPSC platform powers a robust product engine to yield an expansive range of cancer therapies that are designed to avoid host rejection and overcome the suppressive tumor microenvironment, potentially enhancing activity, safety, and durability.